Thursday, February 27, 2025

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Amazon.com, Inc. (AMZN), Eli Lilly and Co. (LLY) and S&P Global Inc. (SPGI), as well as micro-cap stock CVD Equipment Corp. (CVV). The Zacks microcap research is unique as our research content on these small and under-the-radar companies is the only research of its type in the country.

These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Ahead of Wall Street

The daily 'Ahead of Wall Street' article is a must-read for all investors who would like to be ready for that day's trading action. The article comes out before the market opens and attempts to make sense of that morning's economic releases and how they will affect that day's market action. You can read this article for free on our home page and can actually sign up there to get an email notification as this article comes out each morning.

You can read today's AWS here >>> Big Morning for Economic Data: Jobless Claims, GDP & More

Today's Featured Research Reports

Shares of Amazon.com have gained +31.7% over the past year against the Zacks Internet - Commerce industry’s gain of +35.6%. The company’s fourth-quarter results were driven by Prime and AWS momentum. Strengthening AWS services portfolio and its growing adoption rate contributed well to AWS performance. Ultrafast delivery services and expanding content portfolio were beneficial.

Strengthening relationships with third-party sellers was a positive. Robust advertising business contributed well. Amazon’s expanding global presence remains a positive. Growing capabilities in grocery, pharmacy, healthcare and autonomous driving are other positives. Deepening focus on generative AI is a major plus.

However, Amazon announced disappointing guidance for the first quarter. Management cited foreign exchange headwinds and the absence of an extra Leap Year Day as factors likely to impact growth in the current quarter.

(You can read the full research report on Amazon.com here >>>)

Eli Lilly’s shares have outperformed the Zacks Large Cap Pharmaceuticals industry over the past year (+12.1% vs. +1.3%). The company’s Q4 earnings beat estimates while sales missed the same. Demand for popular GLP-1 drugs, Mounjaro and Zepbound, remains strong, making them the company’s key top-line drivers.

In the past two years, Lilly received approvals for some new drugs like Kisunla, Omvoh and Jaypirca. Its new drugs contributed significantly to its top-line growth in 2024. It is also making rapid pipeline progress in areas like obesity, diabetes and Alzheimer’s.

However, sales of Mounjaro/Zepbound were disappointing in the second half of 2024 due to slower-than-expected growth, which has raised concerns about moderating demand for the drugs. Declining sales of Trulicity, rising pricing pressure on some drugs and potential competition in the GLP-1 diabetes/obesity market are some top-line headwinds.

(You can read the full research report on Eli Lilly here >>>)

Shares of S&P Global have outperformed the Zacks Business - Information Services industry over the past year (+24.6% vs. +18%). The company remains well-poised to gain from the growing demand for business information services. Buyouts help innovate, increase differentiated content and develop products.

The latest service launches have been aiding the company's growth and enhancing its market reach. The stock is appealing for the dividend-seeking investors. Share buybacks boost investors' confidence and positively impact earnings per share.

On the flip side, growth initiatives, higher compensations and incentives raise the company's expenses. A highly competitive environment strains the company's market share. Declining liquidity position due to reduction in cash troubles the company. The stock has gained 23.3% in a year and we have a Neutral recommendation on it in anticipation of a correction.

(You can read the full research report on S&P Global here >>>)

CVD Equipment’s shares have underperformed the Zacks Manufacturing - General Industrial industry over the past year (-37.3% vs. +3.1%). This microcap company with market capitalization of $21.2 million faces challenges from silicon carbide (SiC) market overcapacity, fluctuating revenues and declining liquidity, as cash fell to $10 million in third-quarter 2024. The volatile semiconductor sector pressures margins, with a $1 million inventory write-down on PVT150 systems.

Despite setbacks, it reported a 31.4% year-over-year third-quarter revenue growth to $8.2 million, driven by demand in aerospace, defense and high-power electronics. Innovations like the PVT200 for 200mm SiC wafers and PowderCoat systems for EV materials position CVD Equipment for growth in high-demand markets.

Its shift to a make-to-order model enhances scalability, aligning with industry tailwinds in semiconductors, EVs and energy storage. Despite competition and geopolitical risks, R&D investments target growth in EV, aerospace and high-power electronics.

(You can read the full research report on CVD Equipment here >>>)

Other noteworthy reports we are featuring today include Stryker Corp. (SYK), The Southern Co. (SO) and Infosys Ltd. (INFY).

Mark Vickery
Senior Editor

Note: Sheraz Mian heads the Zacks Equity Research department and is a well-regarded expert of aggregate earnings. He is frequently quoted in the print and electronic media and publishes the weekly Earnings Trends and Earnings Preview reports. If you want an email notification each time Sheraz publishes a new article, please click here>>>